Companies › Guerbet
5 active drug programs in 6 registered trials: 5 Phase 4, 1 Phase 3; Oncology, Cardiovascular, Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Gadobenate dimeglumine Gadolinium-based contrast agent for MRI | – | Phase 4 | Motor Function | Dec 2028 |
| Gadodiamide Gadolinium-based contrast agent for MRI | – | Phase 4 | Motor Function | Dec 2028 |
| Gadoterate meglumine Gadolinium-based contrast agent for MRI | – | Phase 4 | Motor Function | Dec 2028 |
| Gadoxetate disodium Gadolinium-based contrast agent for MRI | – | Phase 4 | Motor Function | Dec 2028 |
| gadopiclenol Gadolinium-based MRI contrast agent | – | Phase 3 | Steno-occlusive Disease; Contrast Enhanced Images vs. Non-contrast Images | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06846853 | gadopiclenol | Phase 4 | Contrast Enhanced Images vs. Non-contrast Images | Other | Jun 2026 |
| NCT07348640 | gadopiclenol | Phase 3 | Steno-occlusive Disease | Cardiovascular | Dec 2027 |
| NCT04373564 | Gadoxetate disodium | Phase 4 | Motor Function | Oncology | Dec 2028 |
| NCT04373564 | Gadobenate dimeglumine | Phase 4 | Motor Function | Oncology | Dec 2028 |
| NCT04373564 | Gadodiamide | Phase 4 | Motor Function | Oncology | Dec 2028 |
| NCT04373564 | Gadoterate meglumine | Phase 4 | Motor Function | Oncology | Dec 2028 |
No annotated target.
–
Curium US FutureChem Verity Pharmaceuticals SecuraBio Fidia Farmaceutici
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.